Loading...
XSHG
600993
Market cap1.51bUSD
Jul 10, Last price  
23.25CNY
1D
-2.31%
1Q
-8.68%
Jan 2017
16.42%
IPO
893.59%
Name

Mayinglong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:600993 chart
P/E
17.23
P/S
2.59
EPS
1.35
Div Yield, %
2.61%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
6.73%
Revenues
3.87b
+3.72%
538,328,906548,633,980809,630,9701,021,983,3551,178,494,5801,400,993,7431,542,034,4511,602,282,4761,620,801,1911,783,682,3512,102,806,8951,750,592,3932,197,507,4932,705,396,2422,791,591,9483,385,059,2543,532,379,0373,136,746,4063,728,023,6673,866,608,233
Net income
581m
+10.11%
71,871,238133,403,76180,429,493180,081,085122,538,058137,726,000173,798,452186,324,395201,477,745223,256,090250,243,921320,051,434176,207,929359,967,246419,058,027464,591,721478,571,956443,250,942528,093,863581,492,372
CFO
600m
+20.67%
75,271,3996,485,044102,586,327216,112,501075,366,404169,253,825129,939,557111,670,948182,850,576239,599,870356,168,369308,243,561491,584,397282,988,369597,171,048341,852,836621,742,939497,608,730600,440,356
Dividend
Aug 08, 20250.62 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.
IPO date
May 17, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT